Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Portal Instruments: PFS Addresses Variety of Injection Challenges
October 1, 2023 - Portal Instruments, led by Dr. Patrick Anquetil, PHD, MBA, CEO and Founder, is setting a new standard in drug delivery with its groundbreaking PRIME device. In a special feature, Dr. Anquetil explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability. This needle-free injection device offers a revolutionary approach to high viscosity therapies, addressing challenges such as needle fear, injection pain, and the need for real-time tracking and reminders.
Read the full Drug Development and Delivery special feature here.
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
September 2021 - Patrick Anquetil sat down with ASAP Biopharma ahead of his keynote "Alliance Managers Are Bringing Digital Health Innovation" which is slated for 10:20 a.m. EDT on September 28th. The keynote will be followed by a Q&A session.
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
Please fill out the details below and we will get back to you shortly.